| Dr Junaid Mukhdomi, MD | |
|
5031 Forest Dr Ste C, New Albany, OH 43054-7088 | |
| (614) 647-2526 | |
| (877) 409-2415 |
| Full Name | Dr Junaid Mukhdomi |
|---|---|
| Gender | Male |
| Speciality | Pain Medicine - Interventional Pain Medicine |
| Location | 5031 Forest Dr Ste C, New Albany, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376075135 | NPI | - | NPPES |
| Entity Name | Premier Anesthesia Of Ohio Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699196022 PECOS PAC ID: 3779714258 Enrollment ID: O20140326001267 |
News Archive
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States.
Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A new study from researchers at The Miriam Hospital finds a link between alcohol consumption and reduced condom use among college women. The findings also indicate that women who smoke marijuana with established romantic partners may use condoms less often.
› Verified 6 days ago
| Entity Name | Sandusky Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770907859 PECOS PAC ID: 3274895271 Enrollment ID: O20180402000752 |
News Archive
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States.
Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A new study from researchers at The Miriam Hospital finds a link between alcohol consumption and reduced condom use among college women. The findings also indicate that women who smoke marijuana with established romantic partners may use condoms less often.
› Verified 6 days ago
| Entity Name | Genesis Anesthesia Providers, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295205433 PECOS PAC ID: 0042558066 Enrollment ID: O20190215001836 |
News Archive
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States.
Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A new study from researchers at The Miriam Hospital finds a link between alcohol consumption and reduced condom use among college women. The findings also indicate that women who smoke marijuana with established romantic partners may use condoms less often.
› Verified 6 days ago
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210303002044 |
News Archive
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States.
Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A new study from researchers at The Miriam Hospital finds a link between alcohol consumption and reduced condom use among college women. The findings also indicate that women who smoke marijuana with established romantic partners may use condoms less often.
› Verified 6 days ago
| Entity Name | Pain Zero, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912652603 PECOS PAC ID: 1850787169 Enrollment ID: O20220413000125 |
News Archive
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States.
Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A new study from researchers at The Miriam Hospital finds a link between alcohol consumption and reduced condom use among college women. The findings also indicate that women who smoke marijuana with established romantic partners may use condoms less often.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Junaid Mukhdomi, MD Po Box 738247, Dallas, TX 75373-8247 Ph: (614) 647-2526 | Dr Junaid Mukhdomi, MD 5031 Forest Dr Ste C, New Albany, OH 43054-7088 Ph: (614) 647-2526 |
News Archive
Volcano Corporation, a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Eagle Eye® Platinum digital IVUS catheter in the United States.
Research reported in the October issue of The Journal of Nuclear Medicine (JNM) shows that a molecular imaging technique may prove useful in early assessment of treatment response for cisplatin-resistant ovarian cancer.
Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.
A new study from researchers at The Miriam Hospital finds a link between alcohol consumption and reduced condom use among college women. The findings also indicate that women who smoke marijuana with established romantic partners may use condoms less often.
› Verified 6 days ago
Marcus Harris, M.D. Pain Medicine Medicare: Medicare Enrolled Practice Location: 5031 Forest Dr Ste C, New Albany, OH 43054 Phone: 614-647-2526 Fax: 877-409-2415 |